Jethro HolterInterim CEO
Jethro (born 1972) joined ArcticZymes as Managing Director on January 1st, 2015 and was appointed interim CEO on October 23rd ,2019. He has previous experience from Life Technologies (Thermo Fisher Scientific) in international business development of B2B/OEM solutions with Diagnostic and Life Science companies as well as other sales experience. Earlier in his career, he was R&D Director at Mole Genetics AS developing automated sample prep solutions. Jethro holds a Ph.D in Molecular Neuroscience from Cardiff University, UK. Number of shares in Biotec Pharmacon held by Jethro: 564. Number of options in Biotec Pharmacon held by Jethro: 0
Børge (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a Master’s Degree in Business and Administration from the University of Wyoming. Børge holds 25,428 shares in Biotec Pharmacon.
Rolf (born 1959) holds a M.Sc. in biology and a Ph.D in biochemistry from the University of Tromsø, where he was employed as researcher from 1988 to 1998. Since 1999 he has held the position as R&D manager in Biotec Pharmacon. In September 2006 he was appointed CSO. Number of shares in Biotec Pharmacon held by Rolf: 550,774.
Finn KetlerVice President, Wound Care
Finn Ketler (born 1962) has a M.Sc. degree from Aarhus Business School. Finn has a long and extensive background within medical devices and wound care. He spent 14 years in Coloplast with various roles of increasing responsibility, amongst others managing Coloplast's wound care division. Finn Ketler listed the Swedish medical device start-up Vigmed at Nasdaq First North in Stockholm as a CEO. Finn is acting as a Selection Committee member in BioInnovation Institutes (BII) Incubation programme. Dinn holds 0 shares and options in Biotec Pharmacon.